Abstract:Highlights • To improve the response rate of immune checkpoint inhibitor in triple-negative breast cancer, a self-amplified biomimetic nanosystem was prepared. • The nanosystem displayed an amplified immunogenic cell death (ICD) effect via hydroxyl radical generation and glutathione depletion. • The potent ICD effect has promoted dendritic cells maturation and cytotoxic T lymphocytes infiltration into tumor sites to boost the anti-PD-L1 antibody therapeutic effectto boost the anti-PD-L1 antibody therapeutic effect. To improve the response rate of immune checkpoint inhibitors such as anti-PD-L1 antibody in immunosuppressive cancers like triple-negative breast cancer (TNBC), induction of immunogenic cell death (ICD) at tumor sites can increase the antigenicity and adjuvanticity to activate the immune microenvironment so that tumors become sensitive to the intervention of immune checkpoint inhibitors. Herein, a self-amplified biomimetic nanosystem, mEHGZ, was constructed by encapsulation of epirubicin (EPI), glucose oxidase (Gox) and hemin in ZIF-8 nanoparticles and coating of the nanoparticles with calreticulin (CRT) over-expressed tumor cell membrane. EPI acts as an ICD inducer, Gox and hemin medicate the cascade generation of reactive oxygen species (ROS) to strengthen the ICD effect, and CRT-rich membrane as "eat me" signal promote presentation of the released antigens by dendritic cells (DCs) to invoke the tumor-immunity cycle. The biomimetic delivery system displays an amplified ICD effect via Gox oxidation, hydroxyl radical generation and glutathione (GSH) depletion. The induced potent ICD effect promotes DCs maturation and cytotoxic T lymphocytes (CTLs) infiltration, reversing an immunosuppressive tumor microenvironment to an immunoresponsive one. Treatment with the nanosystem in combination with anti-PD-L1 antibody results in distinctive inhibition of tumor growth and lung metastasis, supporting that a potent ICD effect can significantly boost the therapeutic efficacy of the anti-PD-L1 antibody. This self-amplified biomimetic nanoplatform offers a promising means of raising the response rate of immune checkpoint inhibitors. Graphical abstract A biomimetic nanosystem encapsulates epirubicin (EPI), glucose oxidase (Gox) and hemin in the core of ZIF-8 nanoparticles and coats with calreticulin (CRT) over-expressed tumor cell membranes as the outermost layer (mEHGZ), which induces cascade-amplified ICD effect to promote dendritic cells (DCs) maturation and cytotoxic T lymphocytes (CTLs) infiltration into tumor site. These create an immunoactivated tumor microenvironment to boost anti-PD-L1 antibody therapeutic effect. Download : Download high-res image (379KB) Download : Download full-size image

A peptide-AIEgen nanocomposite mediated whole cancer immunity cycle-cascade amplification for improved immunotherapy of tumor

Reigniting the cancer-immunity cycle with nanoparticles for simultaneous delivery of oncolytic peptides and a TLR agonist

Combination of GNRs-PEI/cGAMP-laden Macrophages-Based Photothermal Induced in Situ Tumor Vaccines and Immune Checkpoint Blockade for Synergistic Anti-Tumor Immunotherapy.

Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor.

Enhanced Immunotherapy Based on Photodynamic Therapy for Both Primary and Lung Metastasis Tumor Eradication

Sequentially Responsive Therapeutic Peptide Assembling Nanoparticles for Dual-Targeted Cancer Immunotherapy

Stepwise Targeting and Tandem Responsive Peptide Nanoparticles Enhance Immunotherapy through Prolonged Drug Retention

A Three-In-One Assembled Nanoparticle Containing Peptide-Radio-Sensitizer Conjugate and TLR7/8 Agonist Can Initiate the Cancer-Immunity Cycle to Trigger Antitumor Immune Response

A combination strategy based on an Au nanorod/doxorubicin gel via mild photothermal therapy combined with antigen-capturing liposomes and anti-PD-L1 agent promote a positive shift in the cancer-immunity cycle

Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles

A novel PD-L1 targeting peptide self-assembled nanofibers for sensitive tumor imaging and photothermal immunotherapy in vivo

Supramolecular Assembled Programmable Nanomedicine As In Situ Cancer Vaccine for Cancer Immunotherapy

Improving combination cancer immunotherapy by manipulating dual immunomodulatory signals with enzyme-triggered, cell-penetrating peptide-mediated biomodulators

A Three-in-One Immunotherapy Nanoweapon Via Cascade-Amplifying Cancer-Immunity Cycle Against Tumor Metastasis, Relapse, and Postsurgical Regrowth

Boosting Theranostic Performance of AIEgens Using Nanocatalyzer for Robust Cancer Immunotherapy

Combination of Bacterial‐Photothermal Therapy with an Anti‐PD‐1 Peptide Depot for Enhanced Immunity Against Advanced Cancer

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.

In Situ Editing of Tumour Cell Membranes Induces Aggregation and Capture of PD-L1 Membrane Proteins for Enhanced Cancer Immunotherapy

A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody

Semiconducting Polymer Nanoparticles with Surface‐Mimicking Protein Secondary Structure As Lysosome‐Targeting Chimaeras for Self‐Synergistic Cancer Immunotherapy

Amplified cancer immunotherapy of PD-L1 blockade by sequential tumor microenvironment reshaping and DC maturation